GlaxoSmithKline has selected Lonza to produce early stage monoclonal antibodies from its biopharmaceutical pipeline. Initially Lonza will manufacture clinical trial batches of five compounds currently in Phase I and II. In addition GSK will also have flexible access to Lonza's capabilities for future demand dependent upon progression of molecules through late stage development and commercial launch.
Reuters
Thursday 9 September 2010
Lonza signs manufacturing deal with GSK
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment